Next Article in Journal
Impact of Surgeon’s Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores
Next Article in Special Issue
Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review
Previous Article in Journal
Inducing Biomechanical Heterogeneity in Brain Tumor Modeling by MR Elastography: Effects on Tumor Growth, Vascular Density and Delivery of Therapeutics

Cannabidiol (CBD) in Cancer Management

by 1,2,3,4
Adelaide Campus, Torrens University, Adelaide, SA 5000, Australia
NICM Health Research Centre, Western Sydney University, Westmead, Sydney, NSW 2145, Australia
Releaf Group Ltd., St Kilda, VIC 3182, Australia
International College of Cannabinoid Medicine,, London N1 7GU, UK
Academic Editors: Grace K. Dy and Aamir Ahmad
Cancers 2022, 14(4), 885;
Received: 6 January 2022 / Revised: 28 January 2022 / Accepted: 5 February 2022 / Published: 10 February 2022
(This article belongs to the Special Issue Integrated Management of Cancer)
Cannabidiol (CBD) is one of the main constituents of the plant Cannabis sativa. Surveys suggest that medicinal cannabis is popular amongst people diagnosed with cancer. CBD is one of the key constituents of cannabis, and does not have the potentially intoxicating effects that tetrahydrocannabinol (THC), the other key phytocannabinoid has. Research indicates the CBD may have potential for the treatment of cancer, including the symptoms and signs associated with cancer and its treatment. Preclinical research suggests CBD may address many of the pathways involved in the pathogenesis of cancers. Preclinical and clinical research also suggests some evidence of efficacy, alone or in some cases in conjunction with tetrahydrocannabinol (THC, the other key phytocannabinoid in cannabis), in treating cancer-associated pain, anxiety and depression, sleep problems, nausea and vomiting, and oral mucositis that are associated with cancer and/or its treatment. Studies also suggest that CBD may enhance orthodox treatments with chemotherapeutic agents and radiation therapy and protect against neural and organ damage. CBD shows promise as part of an integrative approach to the management of cancer.
The plant Cannabis sativa has been in use medicinally for several thousand years. It has over 540 metabolites thought to be responsible for its therapeutic effects. Two of the key phytocannabinoids are cannabidiol (CBD) and tetrahydrocannabinol (THC). Unlike THC, CBD does not have potentially intoxicating effects. Preclinical and clinical research indicates that CBD has a wide range of therapeutic effects, and many of them are relevant to the management of cancer. In this article, we explore some of the potential mechanisms of action of CBD in cancer, and evidence of its efficacy in the integrative management of cancer including the side effects associated with its treatment, demonstrating its potential for integration with orthodox cancer care. View Full-Text
Keywords: cannabidiol; cannabis; endocannabinoid system; cancer; tumours cannabidiol; cannabis; endocannabinoid system; cancer; tumours
Show Figures

Figure 1

MDPI and ACS Style

O’Brien, K. Cannabidiol (CBD) in Cancer Management. Cancers 2022, 14, 885.

AMA Style

O’Brien K. Cannabidiol (CBD) in Cancer Management. Cancers. 2022; 14(4):885.

Chicago/Turabian Style

O’Brien, Kylie. 2022. "Cannabidiol (CBD) in Cancer Management" Cancers 14, no. 4: 885.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop